Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Sana M. Arnouk"'
Autor:
Máté Kiss, Els Lebegge, Aleksandar Murgaski, Helena Van Damme, Daliya Kancheva, Jan Brughmans, Isabelle Scheyltjens, Ali Talebi, Robin Maximilian Awad, Yvon Elkrim, Pauline M. R. Bardet, Sana M. Arnouk, Cleo Goyvaerts, Johan Swinnen, Frank Aboubakar Nana, Jo A. Van Ginderachter, Damya Laoui
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Junctional adhesion molecule-A (JAM-A), expressed on the surface of myeloid cells, is required for extravasation at sites of inflammation and may also modulate myeloid cell activation. Infiltration of myeloid cells is a common feature of tumors that
Externí odkaz:
https://doaj.org/article/0086750d30a3451f83ac10075611fcc7
Autor:
Evangelia Bolli, Maximilian Scherger, Sana M. Arnouk, Ana Rita Pombo Antunes, David Straßburger, Moritz Urschbach, Judith Stickdorn, Karen De Vlaminck, Kiavash Movahedi, Hans Joachim Räder, Sophie Hernot, Pol Besenius, Jo A. Van Ginderachter, Lutz Nuhn
Publikováno v:
Advanced Science, Vol 8, Iss 10, Pp n/a-n/a (2021)
Abstract Tumor‐associated macrophages (TAMs) promote the immune suppressive microenvironment inside tumors and are, therefore, considered as a promising target for the next generation of cancer immunotherapies. To repolarize their phenotype into a
Externí odkaz:
https://doaj.org/article/cac8fa4c5d6f47508fc134a4bcd703ea
Autor:
Els Lebegge, Sana M. Arnouk, Pauline M. R. Bardet, Máté Kiss, Geert Raes, Jo A. Van Ginderachter
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Over the past decade, cancer immunotherapy has been steering immune responses toward cancer cell eradication. However, these immunotherapeutic approaches are hampered by the tumor-promoting nature of myeloid cells, including monocytes, macrophages, a
Externí odkaz:
https://doaj.org/article/e7bef2429bcf49b48de6b85b1e93e993
Autor:
Damya Laoui, Jo A. Van Ginderachter, Mohamed Lamkanfi, Andy Wullaert, Alain Beschin, Massimiliano Mazzone, Diether Lambrechts, Geert van Loo, Geert Raes, Louis Boon, Amelie Fossoul, Ayla Debraekeleer, Jan Brughmans, Maryse Schmoetten, Yvon Elkrim, Sana M. Arnouk, Pauline M.R. Bardet, Jiri Keirsse, Evangelia Bolli, Samantha Pretto, Manuel Ehling, Junbin Qian, Aleksandar Murgaski, Helena Van Damme, Els Lebegge, Pedro H.V. Saavedra, Lieselotte Vande Walle, Máté Kiss
Supplementary Figures 1-11
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ac555aa6d9d63833368748b3be0a555
https://doi.org/10.1158/2326-6066.22543494
https://doi.org/10.1158/2326-6066.22543494
Autor:
Damya Laoui, Jo A. Van Ginderachter, Mohamed Lamkanfi, Andy Wullaert, Alain Beschin, Massimiliano Mazzone, Diether Lambrechts, Geert van Loo, Geert Raes, Louis Boon, Amelie Fossoul, Ayla Debraekeleer, Jan Brughmans, Maryse Schmoetten, Yvon Elkrim, Sana M. Arnouk, Pauline M.R. Bardet, Jiri Keirsse, Evangelia Bolli, Samantha Pretto, Manuel Ehling, Junbin Qian, Aleksandar Murgaski, Helena Van Damme, Els Lebegge, Pedro H.V. Saavedra, Lieselotte Vande Walle, Máté Kiss
IL1β is a central mediator of inflammation. Secretion of IL1β typically requires proteolytic maturation by the inflammasome and formation of membrane pores by gasdermin D (GSDMD). Emerging evidence suggests an important role for IL1β in promoting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17834bb72b19f02c483a544d32dc5d61
https://doi.org/10.1158/2326-6066.c.6550290
https://doi.org/10.1158/2326-6066.c.6550290
Autor:
Damya Laoui, Carola H. Ries, Martina Schmittnaegel, Greetje Vande Velde, Abhishek D. Garg, Sophie Janssens, Sofie Deschoemaeker, Niels Vandamme, Sabine Hoves, Louis Boon, Yvon Elkrim, Victor Bosteels, Ayla Debraekeleer, Ahmed E.I. Hamouda, Sana M. Arnouk, Jan Brughmans, Eva Hadadi, Jiri Keirsse, Isaure Vanmeerbeek, Daliya Kancheva, Helena Van Damme, Máté Kiss, Aleksandar Murgaski
Agonistic αCD40 therapy has been shown to inhibit cancer progression in only a fraction of patients. Understanding the cancer cell–intrinsic and microenvironmental determinants of αCD40 therapy response is therefore crucial to identify responsive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c8705c56f1955289a0b4fab89b0fdd1
https://doi.org/10.1158/0008-5472.c.6514056.v1
https://doi.org/10.1158/0008-5472.c.6514056.v1
Autor:
Damya Laoui, Carola H. Ries, Martina Schmittnaegel, Greetje Vande Velde, Abhishek D. Garg, Sophie Janssens, Sofie Deschoemaeker, Niels Vandamme, Sabine Hoves, Louis Boon, Yvon Elkrim, Victor Bosteels, Ayla Debraekeleer, Ahmed E.I. Hamouda, Sana M. Arnouk, Jan Brughmans, Eva Hadadi, Jiri Keirsse, Isaure Vanmeerbeek, Daliya Kancheva, Helena Van Damme, Máté Kiss, Aleksandar Murgaski
Supplementary Figure from Efficacy of CD40 Agonists Is Mediated by Distinct cDC Subsets and Subverted by Suppressive Macrophages
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08db7c20b68f67424db03239cdfb9dc3
https://doi.org/10.1158/0008-5472.22432053
https://doi.org/10.1158/0008-5472.22432053
Autor:
Damya Laoui, Carola H. Ries, Martina Schmittnaegel, Greetje Vande Velde, Abhishek D. Garg, Sophie Janssens, Sofie Deschoemaeker, Niels Vandamme, Sabine Hoves, Louis Boon, Yvon Elkrim, Victor Bosteels, Ayla Debraekeleer, Ahmed E.I. Hamouda, Sana M. Arnouk, Jan Brughmans, Eva Hadadi, Jiri Keirsse, Isaure Vanmeerbeek, Daliya Kancheva, Helena Van Damme, Máté Kiss, Aleksandar Murgaski
Supplementary Data from Efficacy of CD40 Agonists Is Mediated by Distinct cDC Subsets and Subverted by Suppressive Macrophages
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4aa4636b8a211b411daf06dad31b746
https://doi.org/10.1158/0008-5472.22432511.v1
https://doi.org/10.1158/0008-5472.22432511.v1
Autor:
Aleksandar Murgaski, Máté Kiss, Helena Van Damme, Daliya Kancheva, Isaure Vanmeerbeek, Jiri Keirsse, Eva Hadadi, Jan Brughmans, Sana M. Arnouk, Ahmed E.I. Hamouda, Ayla Debraekeleer, Victor Bosteels, Yvon Elkrim, Louis Boon, Sabine Hoves, Niels Vandamme, Sofie Deschoemaeker, Sophie Janssens, Abhishek D. Garg, Greetje Vande Velde, Martina Schmittnaegel, Carola H. Ries, Damya Laoui
Publikováno v:
CANCER RESEARCH
Agonistic αCD40 therapy has been shown to inhibit cancer progression in only a fraction of patients. Understanding the cancer cell–intrinsic and microenvironmental determinants of αCD40 therapy response is therefore crucial to identify responsive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1616c66e80211e10c1d5b2b8c55db4f5
https://hdl.handle.net/1854/LU-01GTKVARXQ91J23JB6QGJ11KMP
https://hdl.handle.net/1854/LU-01GTKVARXQ91J23JB6QGJ11KMP
Autor:
Ana Rita Pombo Antunes, Tony Lahoutte, Ahmet Krasniqi, Emile J. Clappaert, Aleksandar Murgaski, Kiavash Movahedi, Marnik Vuylsteke, Amanda Gonçalves, Geert Stangé, Nick Devoogdt, Jo A. Van Ginderachter, Geert Raes, Matthias D'Huyvetter, Evangelia Bolli, Danielle Berus, Sana M. Arnouk
Publikováno v:
Journal of Controlled Release. 314:1-11
Radioimmunotherapy (RIT) aims to deliver a high radiation dose to cancer cells, while minimizing the exposure of normal cells. Typically, monoclonal antibodies are used to target the radionuclides to cancer cell surface antigens. However, antibodies